BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raji I, Yadudu F, Janeira E, Fathi S, Szymczak L, Kornacki JR, Komatsu K, Li JD, Mrksich M, Oyelere AK. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem 2017;25:1202-18. [PMID: 28057407 DOI: 10.1016/j.bmc.2016.12.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Hesham HM, Lasheen DS, Abouzid KA. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev 2018;38:2058-109. [DOI: 10.1002/med.21505] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
2 Chen J, Li D, Li W, Yin J, Zhang Y, Yuan Z, Gao C, Liu F, Jiang Y. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Bioorganic & Medicinal Chemistry 2018;26:3958-66. [DOI: 10.1016/j.bmc.2018.06.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
3 Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Peng X, Sun Z, Kuang P, Chen J. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry 2020;208:112831. [DOI: 10.1016/j.ejmech.2020.112831] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
5 Pewklang T, Chansaenpak K, Lai R, Noisa P, Kamkaew A. Aza-BODIPY probe for selective visualization of cyclooxygenase-2 in cancer cells. RSC Adv 2019;9:13372-7. [DOI: 10.1039/c9ra01948k] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
6 Boyd SR, Chang L, Rezende W, Raji IO, Kandel P, Holmes SL, Young DW. Design and Applications of Bifunctional Small Molecules in Biology. Biochim Biophys Acta Proteins Proteom 2021;1869:140534. [PMID: 32871274 DOI: 10.1016/j.bbapap.2020.140534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Guerra Faura G, Wu B, Oyelere AK, France S. Synthetic Methodology-Enabled Discovery of a Tunable Indole Template for COX-1 Inhibition and Anti-cancer activity. Bioorganic & Medicinal Chemistry 2022. [DOI: 10.1016/j.bmc.2022.116633] [Reference Citation Analysis]
8 Beyer M, Romanski A, Mustafa AM, Pons M, Büchler I, Vogel A, Pautz A, Sellmer A, Schneider G, Bug G, Krämer OH. HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1. Cancers (Basel) 2019;11:E1436. [PMID: 31561534 DOI: 10.3390/cancers11101436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tapadar S, Fathi S, Wu B, Sun CQ, Raji I, Moore SG, Arnold RS, Gaul DA, Petros JA, Oyelere AK. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. Cancers (Basel) 2020;12:E3095. [PMID: 33114147 DOI: 10.3390/cancers12113095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Teng Q, Sun G, Luo S, Wang K, Liang F. Design, syntheses and antitumor activities evaluation of 1,5‐diaryl substituted pyrazole secnidazole ester derivatives. J Heterocyclic Chem 2021;58:1656-64. [DOI: 10.1002/jhet.4302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fu RG, Sun Y, Sheng WB, Liao DF. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. Eur J Med Chem 2017;136:195-211. [PMID: 28494256 DOI: 10.1016/j.ejmech.2017.05.016] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 14.2] [Reference Citation Analysis]
12 Qin Z, Xi Y, Zhang S, Tu G, Yan A. Classification of Cyclooxygenase-2 Inhibitors Using Support Vector Machine and Random Forest Methods. J Chem Inf Model 2019;59:1988-2008. [PMID: 30762371 DOI: 10.1021/acs.jcim.8b00876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Stazi G, Fioravanti R, Mai A, Mattevi A, Valente S. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology 2019;50:89-100. [DOI: 10.1016/j.cbpa.2019.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
14 Vaidya GN, Rana P, Venkatesh A, Chatterjee DR, Contractor D, Satpute DP, Nagpure M, Jain A, Kumar D. Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. Eur J Med Chem 2021;209:112844. [PMID: 33143937 DOI: 10.1016/j.ejmech.2020.112844] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Ayyash A, Holloway AC. Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ12,14 PGJ2. J Appl Toxicol 2021. [PMID: 34897744 DOI: 10.1002/jat.4272] [Reference Citation Analysis]
16 Deng Y, Ding T, Deng L, Hao X, Mu S. Active constituents of Zanthoxylum nitidium from Yunnan Province against leukaemia cells in vitro. BMC Chem 2021;15:44. [PMID: 34301301 DOI: 10.1186/s13065-021-00771-0] [Reference Citation Analysis]
17 Caggia S, Tapadar S, Wu B, Venugopal SV, Garrett AS, Kumar A, Stiffend JS, Davis JS, Oyelere AK, Khan SA. Small Molecule Inhibitors Targeting Gαi2 Protein Attenuate Migration of Cancer Cells. Cancers (Basel) 2020;12:E1631. [PMID: 32575572 DOI: 10.3390/cancers12061631] [Reference Citation Analysis]
18 Wu B, Payero B, Taylor S, Oyelere AK. Discovery of novel STAT3 DNA binding domain inhibitors. Future Med Chem 2021;13:1253-69. [PMID: 34180263 DOI: 10.4155/fmc-2021-0088] [Reference Citation Analysis]